Cyclo(-RGDfK) TFA

CAS No. 500577-51-5

Cyclo(-RGDfK) TFA( —— )

Catalog No. M22892 CAS No. 500577-51-5

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 164 In Stock
5MG 96 In Stock
10MG 160 In Stock
25MG 282 In Stock
50MG 384 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cyclo(-RGDfK) TFA
  • Note
    Research use only, not for human use.
  • Brief Description
    Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
  • Description
    Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    αVβ3 integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    500577-51-5
  • Formula Weight
    717.69
  • Molecular Formula
    C29H42F3N9O9
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (139.34 mM; Need ultrasonic); H2O:33.33 mg/mL (46.44 mM; Need ultrasonic)
  • SMILES
    C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O.C(=O)(C(F)(F)F)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
molnova catalog
related products
  • A 286982

    A 286982 is an inhibitor that blocks the integrin-ligand interaction between leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1.

  • GPRP

    GPRP (Gly-Pro-Arg-Pro) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein IIb/IIIa complex (glycoprotein IIb/IIIa receptor).

  • BMS-688521

    BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.